Page 9 - Johnson & Johnson

Johnson & Johnson is willing to pay $400 million-plus in hip-device cases

Company seeks end to Pinnacle hip suits before January trial

J&J implant case: Govt confident of making MNC compensate affected patients

The central government expects to make a legally convincing case on making Johnson & Johnson compensate people for its faultily made hip implants.The multinational company has petitioned the high court at Delhi to argue it is not liable to pay. However, a public interest suit to compel it is pending before the Supreme Court (SC). "Our Drugs and Cosmetics Act did not have a provision for compensation. J&J's main contention is that there is no provision under current law to compensate patients. We have already taken steps to plug the gap. Globally, J&J is paying affected patients, mostly through litigation or out-of-court settlements. There is no reason why they will not compensate the Indian patients," say senior health ministry sources.The implants manufactured by J&J's wholly-owned subsidiary, DePuy International, were faulty, and several instances of revision surgeries were reported in India and across the globe.The laws in several other countrues, said one official

Faulty hip implants case: J&J willing to pay over $400 mn to US consumers

J&J officials have agreed to pay an average of about $125,000 per case to resolve about a third of the suits pending against the company over Pinnacle hips

277 surgeries performed due to faulty J&J hip implants: Minister

A total of 277 revision surgeries have been performed due to the faulty ASR hip implants manufactured by DePuy International Ltd, a subsidiary of Johnson and Johnson, Minister of State for Health Ashwini Choubey told the Rajya Sabha Tuesday. The minister was replying to a question on whether faulty hip implants had resulted in deaths and disability of several patients. "As per the information available with the Central Drugs Standard Control Organisation (CDSCO), 277 revision surgeries were undertaken because of disability due to faulty Articular Surface Replacement (ASR) hip implants manufactured by M/s DePuy International Limited, UK, (now M/s Johnson & Johnson Pvt Ltd)," Choubey said in his reply. He said the government had set up a panel to examine issues relating to the faulty hip implants. The committee, after a detailed examination of the issue, submitted its report to the government, which accepted the recommendations with some modifications. Based on the accepted ...

Setback for Johnson & Johnson's HC plea in hip implants compensation case

Govt had asked J&J to pay compensation to faulty hip implant patients

J&J faulty hip implant row: Noose tightens around medical devices importers

DTAB passed a proposal to include a provision in the MDR for cancellation and suspension of import licence of the medical devices in case of noncompliance with the regulatory provisions

Johnson & Johnson loses cancer drug patent, Indian firms eye US market

Dr Reddy's, Glenmark, Wockhardt have lined up alternatives for Zytiga

From head to toe, J&J is trying to reconquer the baby-care market

After missing out on major shifts in consumer tastes and watching sales stall, the company has remade its baby line. Catching up won't be easy

Patients seek clarity on proposed compensation in J&J faulty implants case

Amid reports that the victims of Johnson & Johnson's faulty hip implants are likely to get as much as Rs 1.2 crore each in compensation, some patients have sought official clarification about the proposed compensation and the basis of deciding on a formula in the absence of any consultation with them. In a letter to Union Health Minister J P Nadda, more than 30 patients have reiterated their concerns regarding the lack of transparency and patient consultation in the process to decide compensation, including lack of information being made available regarding deliberations of the Arya Committee and the formulation of compensation norms. "We are unclear about the basis of deciding on a formula in the absence of any consultation with patients to understand the range of our suffering because of the hip implants, the aggravation of pain and misery caused by unjustifiably delayed medical attention and other negative impacts on our lives. "We question why we have to rely on media reports .

Do J&J hip implant patients need to pay tax on compensation? Find out here

As the money received is capital receipt, it will be tax-free according to income tax provisions

J&J faulty hip transplant: CIC directs RTI disclosure of crucial documents

A Johnson & Johnson subsidiary caught in a controversy over faulty hip replacement systems has opposed RTI disclosure of crucial documents it submitted to the country's drug regulator for seeking import clearance for these devices, the CIC has said. The commission, however, said it has found no impediment in directing disclosure of these compliance documents. Among the records whose disclosure the DePuy Medical Private Limited, the Johnson and Johnson subsidiary, has opposed was an indemnity clause, said Mukesh Jain, the RTI applicant who had sought the information from Central Drugs Standard Control Organisation (CDSCO). The indemnity clause makes companies liable for compensation to patients globally in case equipment are found faulty. The CDSCO, the drug regulator, did not apply the RTI clause of "larger public interest" to provide the documents, Jain told PTI. Instead, he said, it sought the consent of DePuy Medical Private Limited applying the "third party" clause of the Act

Johnson & Johnson to work with govt for recalled hip implants' compensation

MUMBAI (Reuters) - Johnson & Johnson (J&J) said on Friday it would work with the Indian government to compensate patients who suffered from artificial hip implants the U.S. healthcare company recalled eight years ago.

J&J faulty hip implant case: Govt asks all states to form committees

The government has accepted the proposal but has decided to form state-level committees

Tragic delay

Regulatory oversight of Johnson & Johnson case abysmal

Centre to ask Johnson & Johnson to pay up in hip implants case

The central committee will also consider patients suffering on account of monetary loss due to loss of wages and other losses

J&J hip implant case: Panel recommends per person compensation of Rs 2 mn

Recommends per person compensation of Rs 2 million; changes to rules governing medical devices

Johnson & Johnson vows to appeal $4.7 bn talc verdict awarded to 22 women

J&J says decades of testing by laboratories and independent agencies, including a study by the US Food and Drug Administration, support its position

$4.69 bn verdict against Johnson & Johnson over cancer from talc

Investors are likely to increase their focus on the talc cases on the heels of the large award for the plaintiffs

J&J to pay $550 million after lawsuit links cancer to its baby powder

Nearly two dozen women who claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer were awarded USD 550 million in damages by a St Louis jury in the first case against the company that focused on asbestos in the powder. Punitive damages are still to be decided for the 22 plaintiffs in a case that began June 4 in St Louis Circuit Court. Plaintiffs' lawyer Mark Lanier told the jurors during closing arguments on Wednesday that this case was the first where jurors saw documents showing that Johnson & Johnson knew its products contained asbestos and didn't warn consumers, The St. Louis Post-Dispatch reported . "Your voice is not just the voice of the community but the voice of the world," Lanier said. "You don't jack with people's lives like this. ... It's just not right." Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company was disappointed with yesterday's verdict but would not comment further until the punitive damages are

Investors ready to resuscitate Johnson & Johnson's ailing stock

NEW YORK (Reuters) - Johnson & Johnson shareholders have endured a painful year amid worries about prospects for its many businesses, but investors capitalizing on the stock's relatively cheap valuation may be set to apply a Band-Aid to the declines.